TITLE

Prasugrel: A Review of its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

AUTHOR(S)
Duggan, Sean T.; Keating, Gillian M.
PUB. DATE
August 2009
SOURCE
Drugs;Aug2009, Vol. 69 Issue 12, p1707
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summary: Prasugrel (Efient®) is a potent, selective and irreversible inhibitor of adenosine diphosphate (ADP)-mediated platelet aggregation that is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) [comprising unstable angina pectoris/non-ST-segment-elevation myocardial infarction (unstable angina/NSTEMI) and ST-segment-elevation myocardial infarction (STEMI)] undergoing percutaneous coronary intervention (PCI). Oral prasugrel provides rapid, potent inhibition of platelet aggregation and is an effective antiplatelet agent for the management of patients with ACS who are undergoing PCI. In these patients, prasugrel was associated with a significantly lower incidence of ischaemic events than clopidogrel, and was particularly effective in specific subgroups of patients, such as those with diabetes mellitus. However, the efficacy of prasugrel was offset by a higher risk of bleeding than clopidogrel, with patients aged ≥75 years, those weighing <60 kg and those with a history of stroke or transient ischaemic attack at the greatest risk. A lower dose of prasugrel in patients aged ≥75 years and those weighing <60 kg may help to minimize the bleeding risk, although more data are needed to establish this; prasugrel is contraindicated in patients with a history of stroke or transient ischaemic attack. Thus, prasugrel provides a new option for the management of patients with ACS who are undergoing PCI; the risk-benefit ratio should be carefully assessed before intensive antiplatelet therapy with prasugrel is initiated. Pharmacological Properties: Prasugrel is a potent thienopyridine antiplatelet agent that selectively and irreversibly inhibits ADP-induced platelet aggregation mediated by the P2Y 12 receptor. Prasugrel is a prodrug that must first undergo biotransformation to its active metabolite via cytochrome P450-mediated hepatic metabolism. In healthy volunteers, patients undergoing PCI and patients with coronary artery disease, greater and more rapid inhibition of platelet aggregation was seen with prasugrel than with clopidogrel. Inhibition of platelet aggregation occurred ≤1 hour after administration of prasugrel. Metabolism of prasugrel to the active metabolite occurred rapidly with the peak plasma concentrations of the active metabolite reached within ≈30 minutes. Formation of the active metabolite was more rapid and extensive with prasugrel than with clopidogrel, potentially explaining its more rapid onset and greater degree of platelet aggregation inhibition. Therapeutic Efficacy: In a large, randomized, double-blind, multicentre, phase III trial known as the TRITON-Thrombolysis In Myocardial Infarction (TIMI) 38, prasugrel was more effective than clopidogrel in the prevention of ischaemic events during long-term follow-up for up to 15 months in patients with ACS who were undergoing scheduled PCI, as well as during the periprocedural period (first 3 days of treatment). The risk of death from cardiovascular causes, nonfatal myocardial infarction and nonfatal stroke (composite primary endpoint) in patients with unstable angina, NSTEMI or STEMI was significantly lower with prasugrel than with clopidogrel. Landmark analyses demonstrated this effect was apparent both during the first 3 days of treatment and from day 3 until the end of the trial. Prasugrel was also significantly more effective than clopidogrel in reducing ischaemic events in various patient subpopulations, including patients who had received at least one coronary stent and patients undergoing PCI for STEMI, while a more pronounced effect was observed in patients with a history of diabetes. The incidence of recurring cardiovascular events were also significantly lower in prasugrel recipients than in clopidogrel recipients. Tolerability: Bleeding events were the most frequently reported adverse events associated with prasugrel treatment. The incidence of TIMI major bleeding events not related to coronary artery bypass grafting (CABG) was significantly higher with prasugrel than clopidogrel, including the incidence of life-threatening bleeding and fatal bleeding events. Combined non-CABG-related TIMI major and minor bleeding events were also more frequent in prasugrel recipients than in clopidogrel recipients, while a greater percentage of prasugrel than clopidogrel recipients discontinued treatment because of adverse events related to bleeding. Post hocanalyses showed that patients aged ≥75 years and those weighing <60 kg experienced no net benefit, and those with a history of cerebrovascular events experienced net harm and an increased risk of intracranial bleeding compared with clopidogrel. The frequency of serious adverse events not related to bleeding was generally similar between prasugrel and clopidogrel recipients.
ACCESSION #
91988499

 

Related Articles

  • Coronary arterial sling operation. Lund, J.; Kelbaek, H. // Heart;Jul2003, Vol. 89 Issue 7, p744 

    Reports on the case study of a patient with severe myocardial ischemia which occurred ten days after a Q wave infarction treatment with thrombolysis. Detection of three vessel disease of the heart; Performance of coronary angiography; Use of the arterial sling operation.

  • Abciximab: A Pharmacoeconomic Review of its Use in Percutaneous Coronary Revascularisation. Dunn, C.J.; Foster, R.H. // PharmacoEconomics;1999, Vol. 16 Issue 6, p711 

    Abciximab is a monoclonal antibody fragment that inhibits platelet aggregation through antagonism of glycoprotein IIb/IIIa. The drug is used in conjunction with heparin and aspirin to prevent ischaemic complications associated with percutaneous coronary revascularisation in patients with...

  • The Biochemical and Physical Process of Fibrinolysis and Effects of Clot Structure and Stability on the Lysis Rate. Weisel, J. W.; Litvinov, R. I. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 3, p161 

    The effectiveness of fibrinolysis results from the combination of regulated enzymatic activity and the physical properties of the fibrin scaffold. Physiologically, clots or thrombi are dissolved from within via internal lysis. In contrast, with therapeutic thrombolysis, lytic agents are...

  • Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. Maeda, A.; Ando, H.; Asai, T.; Ishiguro, H.; Umemoto, N.; Ohta, M.; Morishima, M.; Sumida, A.; Kobayashi, T.; Hosohata, K.; Ushijima, K.; Fujimura, A. // Clinical Pharmacology & Therapeutics;Feb2011, Vol. 89 Issue 2, p229 

    We examined the influence of CYP2C19 polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine. The platelet aggregation induced by 20 µmol/l adenosine diphosphate (ADP) and CYP2C19 single-nucleotide polymorphisms (*2 and *3) was determined in patients with coronary artery...

  • Stress echo after revascularization may not improve outcomes.  // Pulse International;9/14/2012, Vol. 13 Issue 17, p14 

    The article reports that according to a study published in the journal "Archives of Internal Medicine" repeat coronary revascularization does not improve outcomes in patients with high-risk exercise echocardiography and cites that recurrent ischemia doubled mortality rate in the patients.

  • Drug-eluting Stents. S. Bölükbas; J. Jähne; J. Schirren // Der Chirurg;Jun2009, Vol. 80 Issue 6, p502 

    Zusammenfassung  Die perkutane Koronarintervention (PCI) hat eine besondere Rolle in der Therapie der koronaren Herzerkrankung. „Drug-eluting“ Stents (DES) bedingen eine duale Thrombozytenaggregationshemmung für mindestens ein Jahr. Diese Medikation erschwert planbare und...

  • Hypothermia-induced platelet aggregation and cognitive decline in coronary artery bypass surgery: a pilot study. Hall, Matthew W.; Hopkins, Ramona O.; Long, James W.; Mohammad, S. Fazal; Solen, Kenneth A. // Perfusion;May2005, Vol. 20 Issue 3, p157 

    Hypothermia-induced platelet aggregation (HIPA) was previously reported in whole blood exposed to synthetic surfaces at 24° -32°C in one-third of normal subjects tested. Cardiopulmonary bypass, conducted with hypothermia, may lead to such aggregation, resulting in microvascular occlusion...

  • Drug-Eluting Stents � Pushing the Envelope beyond the Labels? Carrozza, Joseph P. // New England Journal of Medicine;1/24/2008, Vol. 358 Issue 4, p405 

    The author reflects on the controversial use of drug-eluting stents for patients with coronary heart disease. The use of drug-eluting stents became somewhat default with most of the indications being off-label until data suggested a higher rate of patients with thrombotic occlusion who used the...

  • Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]. Kakafika, Anna I.; Mikhailidis, Dimitri P.; Wierzbicki, Anthony S.; Karagiannis, Asterios; Athyros, Vasilios G. // Current Vascular Pharmacology;Jul2007, Vol. 5 Issue 3, p173 

    Full text avialable

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics